Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 847-861 , October 2008

Autoimmune diseases induced by TNF-targeted therapies

  • Manuel Ramos-Casals, MD, PhD (Consultant)

      Affiliations

    • Corresponding Author InformationCorresponding author. Servei de Malalties Autoimmunes, Hospital Clínic, C/Villarroel, 170, 08036-Barcelona, Spain. Tel./Fax: +34-93-2275774.
    • ,
  • Pilar Brito-Zerón, MD, PhD (Trainee in Internal Medicine)
    • ,
  • Maria-Jose Soto, MD, PhD (Consultant)

References 

  1. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Seminars in Arthritis and Rheumatism. 2005;34:7–11
  2. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661–694
  3. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA: The Journal of the American Medical Association. 2006;295:2275–2285
  4. Genovese MC, Bathon JM, Fleischmann RM, et al. Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. The Journal of Rheumatology. 2005;32:1232–1242
  5. Lebwohl M, Gottlieb A, Wallis W, Zitnik R. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. Journal of the American Academy of Dermatology. 2005;52:195
  6. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Current Opinion in Rheumatology. 2006;18:96–100
  7. Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135–147
  8. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–251
  9. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Annals of Internal Medicine. 2002;137:625–626
  10. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Annals of the Rheumatic Diseases. 2005;64:403–407
  11. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism. 2000;43:2383–2390
  12. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Annals of the Rheumatic Diseases. 2002;61:1031–1032
  13. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753–755
  14. Merkel PA. Drug-induced vasculitis. Rheumatic Diseases Clinics of North America. 2001;27:849–862
  15. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Current Opinion in Rheumatology. 2005;17:56–61
  16. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85:95–104
  17. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis and Rheumatism. 1994;37:187–192
  18. Maini RN, Breedveld FC, Kalden JR, et al., Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism. 2004;50:1051–1065
  19. Merkel PA, Lo GH, Holbrook JT, et al. Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of thrombosis (WeCLOT) Study. Annals of Internal Medicine. 2005;142:620–626
  20. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Seminars in Arthritis and Rheumatism. 2008;37:251–255
  21. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. 2003;42:617–621
  22. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheumatic Diseases Clinics of North America. 2004;30:257–270
  23. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis and Rheumatism. 2001;44:2862–2869
  24. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis and Rheumatism. 2004;50:1740–1751
  25. Andrés E, Limbach FX, Goichot B, Sibilia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2002;61:565
  26. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2006;65:889–894
  27. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579–580
  28. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Research & Therapy. 2005;7:R666–R676
  29. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism. 2005;52:2447–2451
  30. Puéchal X, Miceli-Richard C, Mejjad O, et al., Club Rhumatismes et Inflammation (CRI)  Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2008;67:880–884

PII: S1521-6942(08)00105-8

doi: 10.1016/j.berh.2008.09.008

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 847-861 , October 2008

Article Tools